Thein Paul Min, White Kyle, Banker Khyati, Lunny Carole, Mirzaee Sam, Nasis Arthur
Department of Medicine, Monash Medical Centre, Monash Health, Melbourne, Vic, Australia; Monash University, School of Public Health and Preventive Medicine, Melbourne, Vic, Australia.
Monash University, School of Public Health and Preventive Medicine, Melbourne, Vic, Australia.
Heart Lung Circ. 2018 Mar;27(3):310-321. doi: 10.1016/j.hlc.2017.08.026. Epub 2017 Oct 19.
BACKGROUND: Current epidemiological data suggests that postoperative atrial fibrillation or atrial flutter (POAF) causes significant morbidity and mortality after cardiac surgery. The literature for prophylactic management of POAF is limited, resulting in the lack of clear guidelines on management recommendations. AIM: To examine the efficacy of prophylactic rate control agents in reducing the incidence of new-onset POAF in patients undergoing elective cardiac surgery. METHODS: Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and Medline were systematically searched for blinded randomised controlled studies (RCT) evaluating adults with no history of atrial fibrillation randomised to a pharmacological agent (either beta blocker, calcium channel blocker or digoxin), compared to placebo. Utilising Cochrane guidance, three reviewers screened, extracted and the quality of the evidence was assessed. We used a random effects meta-analysis to compare a rate-control agent with placebo. RESULTS: Five RCTs (688 subjects, mean age 61±8.9, 69% male) were included. Beta blocker administration prior to elective cardiac surgery significantly reduced the incidence of POAF (OR 0.43, 95%Cl [0.30-0.61], I=0%) without significant impact on ischaemic stroke (OR 0.49, 95%Cl [0.10-2.44], I=0%), non-fatal myocardial infarction (OR 0.76, 95%Cl [0.08-7.44], I=0%), overall mortality (OR 0.83, 95%Cl [0.19-3.66], I=0%), or length of stay (mean -0.96days 95%Cl [-1.49 to -0.42], I=0%). An increased rate of bradycardic episodes was observed (OR 3.53, 95%Cl [1.22-10.23], I=0%). CONCLUSIONS: This review suggests that selective administration of prophylactic oral beta blockers prior to elective cardiac surgery is safe and may reduce the incidence of POAF.
背景:目前的流行病学数据表明,心脏手术后发生的房颤或房扑(POAF)会导致显著的发病率和死亡率。关于POAF预防性管理的文献有限,导致缺乏明确的管理建议指南。 目的:研究预防性心率控制药物在降低择期心脏手术患者新发POAF发生率方面的疗效。 方法:系统检索Cochrane对照试验中心注册库(CENTRAL)、Embase和Medline,查找评估无房颤病史的成年人随机接受药物治疗(β受体阻滞剂、钙通道阻滞剂或地高辛)与安慰剂对照的双盲随机对照研究(RCT)。按照Cochrane指南,三名 reviewers 进行筛选、提取并评估证据质量。我们使用随机效应荟萃分析来比较心率控制药物与安慰剂。 结果:纳入了五项RCT(688名受试者,平均年龄61±8.9岁,69%为男性)。择期心脏手术前给予β受体阻滞剂可显著降低POAF的发生率(OR 0.43,95%CI [0.30 - 0.61],I = 0%),对缺血性卒中(OR 0.49,95%CI [0.10 - 2.44],I = 0%)、非致命性心肌梗死(OR 0.76,95%CI [0.08 - 7.44],I = 0%)、总体死亡率(OR 0.83,95%CI [0.19 - 3.66],I = 0%)或住院时间(平均 - 0.96天,95%CI [- 1.49至 - 0.42],I = 0%)无显著影响。观察到心动过缓发作率增加(OR 3.53,95%CI [1.22 - 10.23],I = 0%)。 结论:本综述表明,择期心脏手术前选择性给予预防性口服β受体阻滞剂是安全的,可能会降低POAF的发生率。
Cochrane Database Syst Rev. 2018-3-13
Cochrane Database Syst Rev. 2007-1-24
Cochrane Database Syst Rev. 2018-3-2
Cochrane Database Syst Rev. 2004-10-18
J Interv Card Electrophysiol. 2018-3
Cochrane Database Syst Rev. 2021-11-5
Cochrane Database Syst Rev. 2021-11-26
Life Sci. 2022-6-15
Curr Anesthesiol Rep. 2019-6
Cochrane Database Syst Rev. 2019-9-23